NCT01058850终止1 期
A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas
Paul Graham Fisher2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2011年6月最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the EGFRvIII peptide vaccine after conventional radiation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •3.1.1 Patients must be at least 3 years of age and ≤ 18 years of age at the time of study enrollment.
- •3.1.2 Patients must have clinical findings and neuroradiographic findings consistent with diffuse intrinsic pontine glioma. Histologic confirmation of diagnosis is not required for diffuse intrinsic pontine gliomas. A copy of the MRI must be submitted for verification of eligibility.
- •3.1.3 Patients must have received conventional radiation therapy of total radiation dosage ranging from 5400 to 6000 cGy administered in fractions of 150 to 200 cGy over 6 weeks.
- •3.1.4 Treatment must start 14 to 28 days after completion of conventional radiation
- •3.1.5 Patients receiving systemic corticosteroid therapy must be on a tapering or stable low (2 mg twice daily) dose of dexamethasone two weeks after conventional radiation.
- •3.1.6 Patients life expectancy must be greater or equal to 8 weeks.
- •3.1.7 Patients must have a performance status (Lansky or Karnofsky) ≥
- •3.1.8 Platelet count ≥ 100,000/ mm
- •3.1.9 Hemoglobin ≥ 10 g/dL.
- •3.1.10 Creatinine ≤ 2.0 mg/dL.
- •3.1.11 Serum bilirubin ≤ 5.0 mg/dL.
- •3.1.12 If female, patients of childbearing potential must have a negative serum β-hCG pregnancy test.
- •3.1.13 Both male and female patients must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the study.
- •3.1.14 The patient and/or their guardian must have the ability to understand and the willingness to sign a written informed consent document.
- •Exclusion Criteria
- •3.2.1 Prior therapy for diffuse intrinsic pontine glioma, aside from surgery, conventional radiation, and temozolomide.
- •3.2.2 Use of any experimental drug for any reason within the 60 days prior to treatment.
- •3.2.3 Active infection requiring treatment.
- •3.2.4 Known medical condition that, in the opinion of the Investigator, would compromise the patient's ability to participate in the study. This would include chronic active hepatitis infection, known immunosuppressive disease or concurrent neurodegenerative disease.
- •3.2.5 Known allergy or hypersensitivity to any of the components of the vaccine treatment, including GM-CSF, yeast derived products, or a history of anaphylactic reactions to shellfish proteins.
- •3.2.6 Pregnant women and women who are breast-feeding.
排除标准
- 未提供
结局指标
主要结局
Safety
时间窗: Monthly until death or until 5years
次要结局
- Overall survival(Monthly until death or until 5years)
研究者
Paul Graham Fisher
Professor of Pediatrics
Stanford University
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor LinesDiffuse Intrinsic Pontine GliomaNCT02840123Fundació Sant Joan de Déu10
招募中
不适用
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent MeningiomaMeningioma, MalignantNCT04728568Beijing Tiantan Hospital15
已完成
1 期
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.Brain NeoplasmGliomaNCT00040573TransMolecular18
Unknown
2 期
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune ThrombocytopeniaImmune ThrombocytopeniaNCT04289207Seoul National University Hospital55
Unknown
1 期
Anti PD1 Antibody in Diffuse Intrinsic Pontine GliomaDIPGNCT01952769Hadassah Medical Organization50